Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Revuforj

(REH-vyoo-forj)
A drug used to treat adults and children aged 1 year and older with acute leukemia that has a certain change in the KMT2A gene and has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Revuforj binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Also called revumenib citrate.
More Information
Search NCI's Dictionary of Cancer Terms